Shyra Gardai

Shyra Gardai has a diverse and extensive work experience in the field of biotechnology and pharmaceutical research. Shyra began their career as a Graduate Student at the University of Colorado Health Sciences Center in 1997 and continued to work there until 2002.

Following their graduate studies, Gardai joined the National Jewish Medical and Research Center as a Postdoctoral Fellow from 2002 to 2005. Shyra then moved on to the University of Colorado Heath Science Center, where they worked as an Instructor from 2005 to 2006.

In 2006, Gardai joined Elan Pharmaceuticals, where they held multiple roles, starting as a Scientist from 2006 to 2009, followed by positions as Staff Scientist from 2009 to 2011, and finally as Principal Scientist from 2011 to 2012.

Gardai then joined JANSSEN Alzheimer Immunotherapy as a Principal Scientist from 2009 to 2012, gaining further expertise in the field.

In 2013, they transitioned to Second Genome Inc. as an Associate Director, working there for a short period from May 2013 to December 2013.

Gardai then joined Seagen in 2013 and remained with the company until 2023. Shyra held various roles during their tenure, including Principal Scientist from 2013 to 2015, Associate Director from 2015 to 2016, Director from 2016 to 2018, and Senior Director from 2018 to 2019. Shyra then served as Executive Director of Immunology from 2020 to 2021 before being promoted to Vice President of Therapeutic Discovery Research from 2021 to 2023.

Currently, Gardai is working as the Chief Scientific Officer at EpiBiologics, starting in February 2023. This position showcases their extensive experience and leadership in the field.

Shyra Gardai completed their Bachelor of Science degree in Biochemistry/microbiology at the University of Idaho from 1993 to 1997. Shyra then pursued further education at the University of Colorado Anschutz Medical Campus and obtained their Ph.D. in Innate Immunity from 1997 to 2002.